Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price on the stock in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Down 3.8 %

Shares of Brainstorm Cell Therapeutics stock opened at $2.00 on Wednesday. The stock has a market capitalization of $140.16 million, a price-to-earnings ratio of -6.25 and a beta of 0.33. Brainstorm Cell Therapeutics has a twelve month low of $1.96 and a twelve month high of $11.89. The company has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $0.53.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same quarter last year, the company earned ($0.27) earnings per share. On average, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.